Preclinical immune efficacy against SARS-CoV-2 beta B.1.351 variant by MVA-based vaccine candidates

The constant appearance of new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VoCs) has jeopardized the protective capacity of approved vaccines against coronavirus disease-19 (COVID-19). For this reason, the generation of new vaccine candidates adapted to the emer...

Full description

Bibliographic Details

Published in:	Frontiers in Immunology
Main Authors:	Patricia Pérez, Guillermo Albericio, David Astorgano, Sara Flores, Cristina Sánchez-Corzo, Pedro J. Sánchez-Cordón, Joanna Luczkowiak, Rafael Delgado, José M. Casasnovas, Mariano Esteban, Juan García-Arriaza
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-12-01
Subjects:	COVID-19 SARS-CoV-2 MVA-based vaccine variants of concern S protein immunogenicity
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2023.1264323/full